Literature DB >> 9276749

Hepatic gluconeogenic fluxes and glycogen turnover during fasting in humans. A stable isotope study.

M K Hellerstein1, R A Neese, P Linfoot, M Christiansen, S Turner, A Letscher.   

Abstract

Fluxes through intrahepatic glucose-producing metabolic pathways were measured in normal humans during overnight or prolonged (60 h) fasting. The glucuronate probe was used to measure the turnover and sources of hepatic UDP-glucose; mass isotopomer distribution analysis from [2-13C1]glycerol for gluconeogenesis and UDP-gluconeogenesis; [U-13C6]glucose for glucose production (GP) and the direct UDP-glucose pathway; and [1-2H1]galactose for UDP-glucose flux and retention in hepatic glycogen. After overnight fasting, GP (fluxes in milligram per kilogram per minute) was 2.19+/-0.09, of which 0.79 (36%) was from gluconeogenesis, 1.40 was from glycogenolysis, 0.30 was retained in glycogen via UDP-gluconeogenesis, and 0.17 entered hepatic UDP-glucose by the direct pathway. Thus, total flux through the gluconeogenic pathway (1.09) represented 54% of extrahepatic glucose disposal (2.02) and the net hepatic glycogen depletion rate was 0.93 (46%). Prolonging [2-13C1]glycerol infusion slowly increased measured fractional gluconeogenesis. In response to prolonged fasting, GP was lower (1. 43+/-0.06) and fractional and absolute gluconeogenesis were higher (78+/-2% and 1.11+/-0.07, respectively). The small but nonzero glycogen input to plasma glucose (0.32+/-0.03) was completely balanced by retained UDP-gluconeogenesis (0.31+/-0.02). Total gluconeogenic pathway flux therefore accounted for 99+/-2% of GP, but with a glycogen cycle interposed. Prolonging isotope infusion to 10 h increased measured fractional gluconeogenesis and UDP-gluconeogenesis to 84-96%, implying replacement of glycogen by gluconeogenic-labeled glucose. Moreover, after glucagon administration, GP (1.65), recovery of [1-2H1]galactose label in plasma glucose (25%) and fractional gluconeogenesis (91%) increased, such that 78% (0.45/0.59) of glycogen released was labeled (i.e., of recent gluconeogenic origin). In conclusion, hepatic gluconeogenic flux into glycogen and glycogen turnover persist during fasting in humans, reconciling inconsistencies in the literature and interposing another locus of control in the normal pathway of GP.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9276749      PMCID: PMC508308          DOI: 10.1172/JCI119644

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  35 in total

Review 1.  Hepatic glucose metabolism and insulin resistance in NIDDM and obesity.

Authors:  E J Barrett; Z Liu
Journal:  Baillieres Clin Endocrinol Metab       Date:  1993-10

2.  Limitations of the mass isotopomer distribution analysis of glucose to study gluconeogenesis. Substrate cycling between glycerol and triose phosphates in liver.

Authors:  S F Previs; C A Fernandez; D Yang; M V Soloviev; F David; H Brunengraber
Journal:  J Biol Chem       Date:  1995-08-25       Impact factor: 5.157

3.  Measuring gluconeogenesis with [2-13C]glycerol and mass isotopomer distribution analysis of glucose.

Authors:  O Peroni; V Large; M Beylot
Journal:  Am J Physiol       Date:  1995-09

4.  Contribution of hepatic glycogenolysis to glucose production in humans in response to a physiological increase in plasma glucagon concentration.

Authors:  I Magnusson; D L Rothman; D P Gerard; L D Katz; G I Shulman
Journal:  Diabetes       Date:  1995-02       Impact factor: 9.461

5.  Glutamine: a major gluconeogenic precursor and vehicle for interorgan carbon transport in man.

Authors:  N Nurjhan; A Bucci; G Perriello; M Stumvoll; G Dailey; D M Bier; I Toft; T G Jenssen; J E Gerich
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

6.  Use of 2H2O for estimating rates of gluconeogenesis. Application to the fasted state.

Authors:  B R Landau; J Wahren; V Chandramouli; W C Schumann; K Ekberg; S C Kalhan
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

7.  Gluconeogenesis and glucuronidation in liver in vivo and the heterogeneity of hepatocyte function.

Authors:  K Ekberg; V Chandramouli; K Kumaran; W C Schumann; J Wahren; B R Landau
Journal:  J Biol Chem       Date:  1995-09-15       Impact factor: 5.157

8.  Glycogen turnover during refeeding in the postabsorptive dog: implications for the estimation of glycogen formation using tracer methods.

Authors:  E J Barrett; S Bevilacqua; R A DeFronzo; E Ferrannini
Journal:  Metabolism       Date:  1994-03       Impact factor: 8.694

9.  Gluconeogenesis and intrahepatic triose phosphate flux in response to fasting or substrate loads. Application of the mass isotopomer distribution analysis technique with testing of assumptions and potential problems.

Authors:  R A Neese; J M Schwarz; D Faix; S Turner; A Letscher; D Vu; M K Hellerstein
Journal:  J Biol Chem       Date:  1995-06-16       Impact factor: 5.157

10.  Rate of glucose entry into hepatic uridine diphosphoglucose by the direct pathway in fasted and fed states in normal humans.

Authors:  M K Hellerstein; S Kaempfer; J S Reid; K Wu; C H Shackleton
Journal:  Metabolism       Date:  1995-02       Impact factor: 8.694

View more
  36 in total

1.  An Oral Load of [13C3]Glycerol and Blood NMR Analysis Detect Fatty Acid Esterification, Pentose Phosphate Pathway, and Glycerol Metabolism through the Tricarboxylic Acid Cycle in Human Liver.

Authors:  Eunsook S Jin; A Dean Sherry; Craig R Malloy
Journal:  J Biol Chem       Date:  2016-07-18       Impact factor: 5.157

2.  Effects of visceral adiposity on glycerol pathways in gluconeogenesis.

Authors:  Ian J Neeland; Connor Hughes; Colby R Ayers; Craig R Malloy; Eunsook S Jin
Journal:  Metabolism       Date:  2016-11-27       Impact factor: 8.694

Review 3.  Mass spectrometry-based metabolomics.

Authors:  Katja Dettmer; Pavel A Aronov; Bruce D Hammock
Journal:  Mass Spectrom Rev       Date:  2007 Jan-Feb       Impact factor: 10.946

4.  Mechanism by which glucose and insulin inhibit net hepatic glycogenolysis in humans.

Authors:  K F Petersen; D Laurent; D L Rothman; G W Cline; G I Shulman
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

5.  Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo.

Authors:  W H Martin; D J Hoover; S J Armento; I A Stock; R K McPherson; D E Danley; R W Stevenson; E J Barrett; J L Treadway
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

6.  Enhanced glucose cycling and suppressed de novo synthesis of glucose-6-phosphate result in a net unchanged hepatic glucose output in ob/ob mice.

Authors:  R H J Bandsma; A Grefhorst; T H van Dijk; F H van der Sluijs; A Hammer; D-J Reijngoud; F Kuipers
Journal:  Diabetologia       Date:  2004-12-01       Impact factor: 10.122

7.  Deleted in breast cancer 1 (DBC1) protein regulates hepatic gluconeogenesis.

Authors:  Veronica Nin; Claudia C S Chini; Carlos Escande; Verena Capellini; Eduardo N Chini
Journal:  J Biol Chem       Date:  2014-01-10       Impact factor: 5.157

8.  Pituitary adenylate cyclase-activating polypeptide stimulates glucose production via the hepatic sympathetic innervation in rats.

Authors:  Chun-Xia Yi; Ning Sun; Mariette T Ackermans; Anneke Alkemade; Ewout Foppen; Jing Shi; Mireille J Serlie; Ruud M Buijs; Eric Fliers; Andries Kalsbeek
Journal:  Diabetes       Date:  2010-03-31       Impact factor: 9.461

9.  Addressing the current bottlenecks of metabolomics: Isotopic Ratio Outlier Analysis™, an isotopic-labeling technique for accurate biochemical profiling.

Authors:  Felice A de Jong; Chris Beecher
Journal:  Bioanalysis       Date:  2012-09       Impact factor: 2.681

10.  Additional evidence that transaldolase exchange, isotope discrimination during the triose-isomerase reaction, or both occur in humans: effects of type 2 diabetes.

Authors:  Rita Basu; Visvanthan Chandramouli; William Schumann; Ananda Basu; Bernard R Landau; Robert A Rizza
Journal:  Diabetes       Date:  2009-04-14       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.